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Since some of the most modern ion therapy facilities are 
offering or considering the irradiation with alternative ion 
beams, beyond proton and carbon, it has raised new 
attention the need for a proper description of these beams, 
in order to exploit their use for specific applications. In 
particular, helium and oxygen beams are presently available 
in the research cave of the Heidelberg Ion therapy facility 
(HIT). 
We developed and integrated in TRiP98, our research 
treatment planning system, specific beam models for these 
ions, which have been validated experimentally on different 
levels. 
For the Helium beam a semiempirical model for dose 
deposition and fragmentation was implemented, by 
modification of algorithms conventionally used in space 
radiation transport studies, translated to the typical 
therapeutic range of energies [1]. 
For Oxygen beam, the standard transport model of TRiP98 
was tuned on recent attenuation experiments and the 
fragmentation cascade has been improved using the latest 
beam models of the low-lying ions. 
Several treatment planning tests have been performed, 
showing no universal indications but rather selective 
advantages of the different beams, and revealing for 
example a considerable convenience of using Helium beams 
in specific configurations [2], or proposing combination of 
different ions [3]. 
Experimental verification has been performed for both ion 
beams at the experimental room of HIT, analyzing different 
endpoints: basics physics data, delivered 3D physical dose 
distribution and biological effect. Monoenergetic and 
extended target irradiations of different extensions with 
single and double opposed fields have been verified. In the 
case of oxygen beams, considering that its main importance 
is related to a possible indication for partially hypoxic 
tumors, the biological verification was extended beyond the 
RBE weighted dose effect, but also including the OER effect.  
As previously obtained with carbon ions [4], the kill-painting 
method, allowing to restore an homogeneous survival level 
on a differently oxygenated target, was verified with oxygen 
beams. It is found that with the latter ion beams, for a 
partially hypoxic target an inversion of the relative profile 
occurs, as compared to a normoxic case, with a slightly 
reduced normal tissue damage for same  cell killing in the 
target than with  the carbon irradiation. 
 
Keywords: Particle Therapy, Adaptive Treatment Planning, 
Helium beams, Oxygen beams, Hypoxia 
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The demand for personalized medicine is increasing, and 
considering that the population suffering from chronic 
diseases (i.e. cancer, Alzeihmer) is continuously growing it is 
expected that the consumption of molecular diagnostic 
products and radiotherapeutics will continue to increase. In 
this scenario, TRIUMF and its fleet of proton accelerators 
ranging from 13 to 500 MeV is offering a unique environment 
for scientists to enable the production of isotopes with 
potential applications in molecular imaging or radiotherapy. 
A multidisciplinary program involving target design, isotope 
production and radiopharmaceutical chemistry has emerged 
in the Division of Life Sciences to facilitate and accelerate 
the translation from bench-to-bedside. 
A brief overview of the recent efforts related to the 
production and applications of medical isotopes at TRIUMF 
will be presented. Comprehensive studies have been 
conducted to improve the production of conventional PET 
isotopes by a better understanding of the physical 
phenomenon occurring inside the target during beam 
irradiation. Feasibility of the production, from liquid targets, 
of radiometals (i.e. 44Sc, 68Ga, 86Y and 89Zr) used in medical 
imaging has also been demonstrated. The results of the ITAP 
project, led by TRIUMF and including a consortium of 
institutions, on accelerator-based production of 99mTc will be 
discussed. It has been shown that a reliable commercial scale 
(TBq) production of 99mTc is achievable by using 100Mo coated 
tantalum targets at energies up to 24 MeV. Investigations on 
the production and isolation of the therapeutic isotope 211At 
and its imaging companion 209At will be mentioned.  
Novel radiolabeling strategies and technologies have recently 
emerged to prepare radiopharmaceuticals and will be 
discussed. Isotopic exchange reactions are getting popular to 
rapidly and efficiently synthesize PET imaging probes. Click 
chemistry is also representing an attractive approach to 
radiolabel molecules because of its simple process, short 
reaction times and clean product synthesis. Microfluidic 
devices bear great promises in the field of radiochemistry as 
it is expected that they will allow faster reaction rate, 
exquisite reaction selectivity, reduced reagent consumption, 
and possibly revisit the hot-lab concept. An overview of the 
tracer development performed at TRIUMF (e.g. cysteine 
transporter, angiogenesis) will be presented. 
Finally, within the framework of the MEDICIS-PROMED 
consortium, a collaboration between TRIUMF and the 
Institute of Translational Molecular Imaging (ITMI) at the 
University Hospital of Geneva and the Laboratory of 
Bioorganic Chemistry and Molecular Imaging at EPFL will soon 
take place. This presentation will conclude with a short 
summary of our ambitious project on the development of 
dual modality molecular probes for ovarian cancer and their 
preclinical validations in animal models. 
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Purpose: The main purpose of the present work is to evaluate 
the effects of gold nanoparticles (GNPs) in different sizes and 
concentrations on cancer cells which undergo treatment with 
photon therapy.  
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Material and Method: This work was carried out with MCNP 
and Geant4 codes. The 10x10x10 cm3 cubic water phantom 
and a tumor region with a size of 1x1x1 cm3 were simulated. 
Factors such as different concentrations and GNP sizes were 
implemented into the simulation, so as to obtain the 
optimum results, specifying the maximum absorbed dose 
within the tumor while sparing healthy tissue. In a certain 
concentration, different sizes of GNPs including 30, 50, 70 
and 100 nm were defined within the tumor and the absorbed 
dose by the GNPs-loaded tumor were calculated for different 
sizes. Similarly, the absorbed dose was calculated for 
different concentrations of 7, 10, 18 and 30 (mg Au/ gram of 
tumor) in a certain size of GNPs. The dose enhancement 
factor which is defined as the ratio of the absorbed dose by 
the tumor in the presence of nanoparticles to the absorbed 
dose by the same organ in the absence of nanoparticles was 
estimated for different concentrations and sizes of GNPs. 
Results and Conclusion: The calculations show results for 
different sizes and concentrations and a comparison is made 
between the two Monte Carlo codes (MCNP and Geant4). In a 
certain diameter of GNPs the higher concentration made 
more increase in absorbed does by the tumor. In a certain 
concentration, higher size of GNPs made higher absorbed 
dose by the tumor. Given the fact that therapeutic 
applications of GNPs in acquiring the proper DEF have 
demanded much attention in recent years, defining the 
proper size and concentration would be considered extremely 
vital for pre-treatment plans. 
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Purpose: Aim of this study was to investigate, practically 
prove contribution, and verify dosimetry possibilities for low-
risk patients (rhTSH stimulation and 1.1 GBq 131I 
administration) undergoing first Radioiodine therapy (RAIT). 
Furthermore, it was intended to verify whether the 
administered activity deliver sufficient dose to thyroid 
remnants so it can be called ”thyreo-ablative”.   
Materials and methods: Siemens Symbia S gamma camera was 
used for quantitative imaging of 131I accumulation in 
remnants of patients thyroid and 131I accumulating nods. 
Vials with known activity of 131I were used to calibrate the 
system. Verification of activity determination was done by 
measuring the vial together with patient for comparison, if 
necessary. All of the patient-volunteers were around 3 
months after thyreoablation due to thyroid carcinoma. As a 
low-risk indicated patients, they were prepared by injections 
of rhTSH during two days before therapy. Weight of the 
accumulating remnants or nods was established using 
ultrasound, if visible or roughly estimated using phantom 
measurements causing serious uncertainties. 
17 patients (15 women, 2 men) participating the study 
undergone up to 6 quantitative imaging by the gamma 
camera during 70 hours after administration. Minimum of the 
gamma camera examination was 4. General time schedule of 
examination was 5, 24, 30, 48, 70 hours after administration. 
  
Results: Absorbed doses within remnants or nodes vary from 
tens of Gy up to several hundred Gy with uncertainty from 
25% up to 100% depending mainly on mass of the remnants 
estimation. For 5 of the patient the administered therapeutic 
activity caused absorbed dose which was considered to be 
rather insufficient in terms of thyreo-elimination (at least for 
one of accumulating remnants). For 4 patients the absorbed 
dose was considered to be particularly thyreo-eliminative. 
Measurements for 5 patients confirmed thyreo-eliminative 
dose and in case of 3 patients no accumulation was detected. 
Consequent follow-up for all patients is being done. 
Conclusions: Though in nearly 30% of all patients absorbed 
dose did not reach 300 Gy in thyroid remnants and 80 Gy in 
nods, due to low-risk staging it is probable that the 
treatment was successful. However, it is necessary to do 
consequent follow up and include all data for annual 
treatment evaluation. Based on the results appropriate grant 
for further investigation will be seek out. 
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Purpose: Particle therapy cancer treatments require a work 
flow that involve several professional figures, working with a 
complex hardware and software set up. Each professional 
role needs access to a considerable set of information in the 
everyday clinical practice. In particular quality assurance 
protocols demand checking a sensible amount of data. 
The drawback is that often required information are 
physically accessible outside the treatment room, being 
distributed on several computer in different places. 
Integrate and display needed information in an organic and 
easily accessible way can speed up the clinical practice, 
reducing potential time loss and providing a better 
continuous quality control. 
Methods: We propose an innovative tool based on Augmented 
Reality (AR). In AR a view of the physical world is augmented 
with computer generated elements. Our AR tool could be 
installed on a modern mobile device, a tablet or a cellphone. 
Users gets information in real-time about any equipment in 
the treatment room simply pointing the device at it. 
The AR client recognizes medical equipment using the device 
camera, then gathers corresponding information from a cloud 
server, where all data stored. 
The access to the data server is secured with different level 
of privileges: a user can visualize and use only predetermined 
kind of relevant information, according to his role. Moreover, 
all information related to the patient and the medical 
environment are hosted in a private cloud, not accessible 
without proper authentication. 
Results: We present a prototype of AR application for particle 
therapy centre that improves and speeds up the whole work 
flow, making the access to information easier and more 
centralized. 
Here we present a three different use cases that illustrate 
the use of our AR application: medical doctor, medical 
physicists and technical engineer. 
Conclusion: Augmented Reality is the perfect candidate to 
help healthcare organizations make their existing processes 
more precise and efficient. Using AR tools, useful information 
can be provided and related in real-time to the specific need 
of the different systematic tasks that are daily checked 
accurately in an advance radiation therapy facility. 
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R-NAV, LLC 
 
Sn-117m has unique characteristics that make it ideal for a 
variety of nuclear medicine applications.  The t1/2=14d 
isotope emits a primary 159 keV imaging photon (86%) that is 
easily detectable with any SPECT camera system. The 
accompanying mono-energetic conversion electrons (~140 
keV; 110%) have a therapeutic effect limited to a range of 
~300 μm which also minimizes any shipping and handling 
issues.  Together these characteristics make this theranostic 
